Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH

Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH

Dana-Farber’s Breast Oncology Center posted on X:

“We are leading a randomized Phase 2 trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0).”

Read further.
Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer cancer clinical trial Dana-Farber Cancer Center Dana-Farber’s Breast Oncology Center HER2+ breast cancer OncoDaily Oncology Paclitaxel trastuzumab